{"id":3579,"date":"2026-01-19T14:46:47","date_gmt":"2026-01-19T13:46:47","guid":{"rendered":"https:\/\/fhucare.com\/?page_id=3579"},"modified":"2026-02-02T15:32:58","modified_gmt":"2026-02-02T14:32:58","slug":"tnf-sen","status":"publish","type":"page","link":"https:\/\/fhucare.com\/fr\/research-projects\/tnf-sen\/","title":{"rendered":"TNF Sen"},"content":{"rendered":"\n

Leaders : Nathalie Chaput<\/a>-Gras, <\/strong>Ga\u00ebtane Nocturne<\/strong><\/a>, Marie Naigeon<\/strong><\/a><\/p>\n\n\n\n

Scientific publication : Expanded senescent CD8 T cells in IMID patients are associated with distinct inflammatory cytokines<\/a><\/strong><\/p>\n\n\n\n

Clinical and Experimental Immunology, Volume 219, Issue 1, 2025, uxaf050<\/p>\n\n\n\n

\"\"<\/a><\/figure>\n\n\n\n

Clin Exp Immunol<\/em>, Volume 219, Issue 1, 2025, uxaf050, https:\/\/doi.org\/10.1093\/cei\/uxaf050<\/a><\/p>\n\n\n\n

<\/p>\n\n\n\n

Etude des marqueurs de s\u00e9nescence lymphocytaire sous anti-TNF\u03b1<\/strong>Rationnel de l\u2019\u00e9tude : SIP: LT CD8+ CD28- CD57+ KLRG1+<\/strong>SIP and prognosis<\/strong><\/p>\n\n\n\n

Pubmed :<\/p>\n\n\n\n

\n

Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1\/PD-L1 Inhibitors or Platinum-based Chemotherapy.<\/strong><\/a><\/p>\n\n\n\n

Ferrara R, Naigeon M<\/strong>, Auclin E, Duchemann B, Cassard L, Jouniaux JM, Boselli L, Grivel J, Desnoyer A, Mezquita L, Texier M, Caramella C, Hendriks L, Planchard D, Remon J, Sangaletti S, Proto C, Garassino MC, Soria JC, Marabelle A<\/a><\/strong>, Voisin AL, Farhane S, Besse B<\/a>, Chaput N.<\/a><\/strong>
Clin Cancer Res<\/strong>. 2021 Jan 15;27(2):492-503. doi: 10.1158\/1078-0432.CCR-20-1420. Epub 2020 Sep 4.<\/p>\n<\/div>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Pr. Chaput<\/a><\/strong> and Pr. Nocturne<\/a> <\/strong>are presenting a collaborative project exploring cell senescence and its implication in autoimmune diseases, cancer and chronic viral infections.<\/p>\n\n\n\n

<\/p>\n\n\n\n

The objective of this project is to understand the potential common and opposing mechanisms leading to T cell senescence and the means to control it in autoimmunity, cancer and chronic viral infections.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

In this context, Pr. Carbonnel<\/a><\/strong> suggested exploring Crohn’s disease as part of this project.<\/p>\n\n\n\n

Pr. Mariette<\/a> <\/strong>noted that this collaborative work perfectly embodies the spirit of the FHU CARE, which aims to create synergies between teams.<\/p>\n\n\n\n

<\/p>\n\n\n\n

Rationnel de l’\u00e9tude SIP: LT CD8+ CD28- CD57+ KLRG1+<\/strong><\/h3>\n\n\n\n
\n
\n
\n
\n

1<\/p>\n<\/div>\n\n\n\n

SIP & Cancer<\/strong><\/p>\n\n\n\n

Un ph\u00e9notype immunitaire s\u00e9nescent (SIP) est observ\u00e9 chez les patients atteints de CBNPCa et pr\u00e9dit la r\u00e9sistance aux
anti-PD-1\/PD-L1<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n
\n

2<\/p>\n<\/div>\n\n\n\n

SIP & Inflammation<\/strong><\/p>\n\n\n\n

L’inflammation chronique pourrait favoriser les LT s\u00e9nescents<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n
\n

3<\/p>\n<\/div>\n\n\n\n

SIP & anti-TNF\u03b1<\/strong><\/strong><\/p>\n\n\n\n

Chez des patients atteints de MAI, les anti-TNF pourraient modifier le SIP et \u00eatre utile pour am\u00e9liorer l’efficacit\u00e9 des anti-PD-1 dans le cancer.<\/p>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n

Outline of the clinical trial<\/strong><\/h3>\n\n\n\n
\"\"<\/figure>\n\n\n\n

Our first results?<\/strong><\/h3>\n\n\n\n

Pr. Chaput<\/a> <\/strong>and Pr. Nocturne<\/a><\/strong> present a collaborative project to explore lymphocyte senescence and its implication in autoimmune diseases and cancer.<\/p>\n\n\n\n

Pr. Chaput’s team has demonstrated the presence of senescent CD8+ T cells in lung cancer patients and high levels of these cells would be associated with resistance to anti-PD-(L)1 antibody. In addition to the physiological immune aging with age, senescent T cells can accumulate following chronic antigenic stimulation (cancer, autoimmune diseases) or in inflammatory diseases such as diabetes.<\/p>\n\n\n\n

The objective of TNFSEN is to study T cell senescence in autoimmune diseases (rheumatoid arthritis, ankylosing spondylitis and Sj\u00f6gren’s syndrome) and its evolution during anti-TNF-\u03b1 treatment. This study will allow to investigate common or opposite mechanisms leading to senescence, in cancer and autoimmune diseases.<\/p>\n\n\n\n

In this context, Pr. Franck Carbonnel<\/a> <\/strong>suggested exploring Crohn’s disease. This collaborative work perfectly embodies the spirit of the FHU, which aims to create synergies between teams.<\/p>\n\n\n\n

Recently, a first analysis on cytometry data and assays of factors associated with inflammation was conducted.<\/p>\n\n\n\n

Since 2022, Sj\u00f6gren\u2019s disease and cytokine measurements have been added. Key results<\/strong> :<\/p>\n\n\n\n